Bladder Cancer Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Recruiting
- Urothelial Carcinoma
- Bladder Cancer
- Atezolizumab
- +8 more
- Los Angeles, California
- +33 more
2022-04-07
Apr 7, 2022N
Recruiting
- Bladder Cancer
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022V
Not yet recruiting
- Bladder Cancer
- +5 more
- Bacillus Calmette-Guerin: Strain Russian BCG-I
- Bacillus Calmette-Guerin: Strain TICE
- (no location specified)
2022-04-07
Apr 7, 2022N
Not yet recruiting
- Urothelial Cancer
- +4 more
- Washington, District of Columbia
- +2 more
2022-04-07
Apr 7, 2022I
Recruiting
- Ovarian Cancer
- +10 more
- West Hollywood, California
- +26 more
2022-04-06
Apr 6, 2022N
Recruiting
- Urothelial Cancer
- +4 more
- M7824
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Bladder Cancer
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Bladder Cancer
- intravesical mitomycin-C 40mg/20ml instillation
- Goyang, Korea, Republic ofNational Cancer Center
2022-04-05
Apr 5, 2022C
Active, not recruiting
- Bladder Cancer
- Los Angeles, California
- +3 more
2022-04-05
Apr 5, 2022M
Recruiting
- Bladder Cancer
- +2 more
- Basking Ridge, New Jersey
- +6 more
2022-03-29
Mar 29, 2022G
Recruiting
- Urothelial Carcinoma
- +4 more
- Trilaciclib
- +4 more
- Whittier, California
- +41 more
2022-04-05
Apr 5, 2022H
Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma
Not yet recruiting
- Bladder Cancer
- FGFR test
- (no location specified)
2022-04-06
Apr 6, 2022A
Recruiting
- Pancreatic Cancer
- +7 more
- Glasgow, United Kingdom
- +5 more
2022-04-05
Apr 5, 2022S
Active, not recruiting
- Bladder Cancer
- therapeutic conventional surgery
- +2 more
- Los Angeles, California
- +34 more
2022-04-04
Apr 4, 2022A
Recruiting
- Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
- +12 more
- ADCT-301
- Pembrolizumab
- Palo Alto, California
- +9 more
2022-03-24
Mar 24, 2022S
Not yet recruiting
- Small Cell Neuroendocrine Carcinoma of Bladder
- +2 more
- Atezolizumab
- +4 more
- Washington, District of Columbia
- +1 more
2022-03-28
Mar 28, 2022D
Recruiting
- Bladder Cancer
- Urothelial Carcinoma
- 18F-fluciclovine
- PET/CT
- Boston, MassachusettsDana Farber Cancer Institute
2022-04-04
Apr 4, 2022S
Recruiting
- Non-small Cell Lung Cancer
- +11 more
- Birmingham, Alabama
- +26 more
2022-04-01
Apr 1, 2022I
Recruiting
- Bladder Cancer
- Urine collection (150ml)
- Blood sample (20 ml)
- Vandœuvre-lès-Nancy, FranceInstitut de Cancérologie de Lorraine
2022-03-23
Mar 23, 2022I
Active, not recruiting
- Bladder Cancer
- +3 more
- IPI-549 (eganelisib)
- +2 more
- Fort Wayne, Indiana
- +28 more
2022-04-01
Apr 1, 2022G
Active, not recruiting
- Neoplasms
- +4 more
- Trastuzumab
- +7 more
- Goodyear, Arizona
- +60 more
2022-04-01
Apr 1, 2022M
Recruiting
- Breast Cancer
- +6 more
- PCR/PCR/LDR Strategy
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-04-01
Apr 1, 2022A
Completed
- Non-small Cell Lung Cancer
- +11 more
- Scottsdale, Arizona
- +14 more
2022-03-31
Mar 31, 2022P
Recruiting
- Bladder Cancer
- New York, New York
- +1 more
2022-03-21
Mar 21, 2022N
Recruiting
- Malignant Neoplasms
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022